ASCO Annual Meeting

ASCO 2026 data show GLP-1 RAs reduce HR+/HER2- breast cancer risk and improve overall survival in non-diabetic women with a BMI of 25-35 kg/m².

Oncology nurses play a vital role in managing cognitive and metabolic toxicities during long-term lorlatinib therapy for ALK+ NSCLC.

New ASCENT-04 data shows sacituzumab govitecan plus pembrolizumab improves PFS in first-line PD-L1+ TNBC regardless of Trop-2, BRCA, or HER2 status.

ASCO 2026: Dr. Shubham Pant discusses managing the unique side effect profile of daraxonrasib, a new standard of care for metastatic pancreatic cancer.

ASCO 2026: The EMERALD-3 study shows adding STRIDE with or without lenvatinib to TACE significantly extends PFS for patients with unresectable HCC.

ASCO 2026: Adding ipatasertib to pembrolizumab improved ORR to 41% in first-line R/M HNSCC, significantly outperforming pembrolizumab monotherapy.

A large real-world analysis found that higher frailty scores were associated with increased odds of toxicities, hospitalization, and mortality in patients receiving ADC, BiTE, and CAR T-cell therapies.

A real-world study shows concurrent GLP-1 RA and ICI use may significantly improve long-term survival and lower toxicities for patients with cancer.

Dr. Emily Podany explains how oncology nurses can screen for food insecurity and provide evidence-based solutions to improve patient outcomes.

Dr. Paolo Tarantino highlights the need for drug-specific prophylaxis to manage toxicities like ILD and neutropenia in patients receiving ADCs.

Final KEYNOTE-522 analysis shows 85.1% 7-year OS in early TNBC. Dr. Javier Cortes details nursing management of immune-related side effects.

An updated post hoc analysis showed that imetelstat nearly doubled overall survival compared with best available therapy in patients with JAK inhibitor–relapsed or refractory myelofibrosis.

The phase 2 ARACOG study is the first head-to-head randomized comparison of cognitive effects between the 2 androgen receptor pathway inhibitors.

Studies to be presented at the 2026 ASCO Annual Meeting examine GLP-1 receptor agonists in relation to cancer progression, survival, and immune-related adverse events.

As CAR T-cell therapy expands to solid tumors, oncology nurses play a key role in monitoring, educating, and supporting patients.

ALLO-316 showed significant activity and safety in patients with metastatic CD70-positive clear cell renal cell carcinoma.

Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus panitumumab in CRC.

In addition to a significant PFS benefit vs nab-paclitaxel alone, the combination provides an at-home option for patients with ovarian cancer.

Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.

Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.

Lasting survival benefits vs chemotherapy or monotherapy were achieved with nivolumab and ipilimumab for patients with MSI-H/ dMMR metastatic colorectal cancer.

T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.

A machine learning model applied to CheckMate 9ER may help predict outcomes and resistance in advanced renal cell carcinoma.

Olanzapine plus an antiemetic shows potential in preventing RINV while reducing other adverse events such as depression, appetite loss, and insomnia.

Final KEYNOTE-A18 results show sustained survival benefit with pembrolizumab plus concurrent chemoradiation in locally advanced cervical cancer.

The ROR1-targeted ADC plus R-GemOx led to a 56.3% ORR in patients with relapsed or refractory diffuse large B-cell lymphoma in waveLINE-003.

Luspatercept led to durable red blood cell transfusion independence and early OS signals in ESA-naive, lower-risk MDS, per updated COMMANDS data.

By monitoring patients’ CBC and other symptoms, nurses and advanced practice providers can spot early indicators of parkinsonism risk, per Yi Lin, MD, PhD.

A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, leading to prolonged survival.

Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a second-line standard of care.